Skip to main content
SpringerLink
Log in

Molekularpathologische Analyse beim metastasierten NSCLC

EGFR-Mutationsstatus als prädiktiver Biomarker

Molecular pathological analysis of metastasized NSCLC

EGFR mutation status as predictive biomarker

  • Außer der Reihe
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Pirker R, Szczesna A, von Pawel J et al (2008) FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbin (CV) versus CV alone in the first-line treatment of patients with advanced non-small lung cancer (NSCLC). Proc Am Soc Clin Oncol 26(Suppl):S1006; Abstr. #3

    Google Scholar 

  2. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab fon non-small cell lung cancer. N Engl J Med 355:2542–2550

    Article  PubMed  CAS  Google Scholar 

  3. Manegold C et al (2008) A phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine in aptients with advanced or recurrent non-squameous non-small cell lung cancer. ESMO; Abstr. #LAB1

  4. Shepherd FA, Rodriguez-Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123–132

    Article  PubMed  CAS  Google Scholar 

  5. Mok T, Wu l, Thongprasert S et al (2008) Phase III, randomized, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) (IPASS). Ann Oncol 19(Suppl.8) LBA2

  6. Suzuki T, Nakagawa T, Endo H et al (2003) The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inihibitors ZD1839 (Iressa) is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer 42:35–41

    Article  PubMed  Google Scholar 

  7. Fukuoka M, Wu Y, Thongpraset C et al (2009) Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/Paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). Proc Am Soc Clin Oncol Abstr. #8008

  8. Sharma SV, Bell DW, Settleman J et al (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169–181

    Article  PubMed  CAS  Google Scholar 

  9. Paez JG, Janna FA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500

    Article  PubMed  CAS  Google Scholar 

  10. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness on non-small cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  PubMed  CAS  Google Scholar 

  11. Capuzzo F, Hirsch FR, Rossi E et al (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 97:643–655

    Article  Google Scholar 

  12. Cortes-Funes H, Gomez C, Rosell R et al (2005) Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small cell lung cancer patients. Ann Oncol 16:1081–1086

    Article  PubMed  CAS  Google Scholar 

  13. Han SW, Kim TY, Hwang PG et al (2005) Predictive and prognostic impact of epidermal growth factor receptor mutations in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493–2501

    Article  PubMed  CAS  Google Scholar 

  14. Takano T, Ohe Y, Sakamoto H et al (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small cell lung cancer. J Clin Oncol 23:6829–6837

    Article  PubMed  CAS  Google Scholar 

  15. Mitsudomi T, Kosaka T, Endoh H et al (2005) Mutations of the epidermal growth factor receptor gene predicts prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513–2520

    Article  PubMed  CAS  Google Scholar 

  16. Taron M, Ichinose Y, Rosell R et al (2005) Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11:5878–5885

    Article  PubMed  CAS  Google Scholar 

  17. Mitsudomi T, Yatabe Y (2007) Mutations of the epidermal growth factor recpetor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98:1817–1824

    Article  PubMed  CAS  Google Scholar 

  18. Dietel M, Tannapfel A, Baretton G et al (2008) Molekularpathologische Analyse des K-RAS-Mutationsstatus beim metastasierten kolorektalen Karzinom. Onkologe 2008; DOI 10.1007/s00761-008-1367-4

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung/en hin: tätig im wissenschaftlichen Advisory Board von Astra Zeneca.

Author information

Authors and Affiliations

  1. Institut für Pathologie, Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin, Deutschland

    M. Dietel

  2. Institut für Pathologie, Universitätsklinik Heidelberg, Heidelberg, Deutschland

    P. Schirmacher

Authors
  1. M. Dietel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Schirmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Dietel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dietel, M., Schirmacher, P. Molekularpathologische Analyse beim metastasierten NSCLC. Onkologe 16, 63–66 (2010). https://doi.org/10.1007/s00761-009-1737-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-009-1737-6

Search

Navigation